Kevin Balthaser insider trades
Open-market stock purchases and sales by Kevin Balthaser, Chief Financial Officer at Aclaris Therapeutics, Inc, from SEC Form 4 filings since Feb 1, 2023.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -23%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Mar 1, 2026 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $1.9K |
| Mar 1, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Feb 3, 2026 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $22.4K |
| Feb 3, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Feb 2, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Feb 2, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Feb 1, 2026 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $17.5K |
| Feb 1, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Jan 2, 2026 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $12.8K |
| Jan 2, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Jan 1, 2026 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $6.8K |
| Jan 1, 2026 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
| Dec 31, 2025 | ACRS Aclaris Therapeutics, Inc | Sold (not open market) | $60K |
| Dec 31, 2025 | ACRS Aclaris Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- ACRS Aclaris Therapeutics, Inc: 1 buy, 2 sales, last Mar 1, 2026